Moreover, the addition of the selective Mcl-1 inhibitor S63845 [41, 42], AMG 176, or AM-8621 [43] enhances the sensitivity to venetoclax in AML cell lines as well as in primary AML cells. The gene discussed is MCL1; the disease is acute myeloid leukemia.